Biomet Hip Lawsuits Mount, as Filings in Federal Litigation Exceed 2,200 Cases, Bernstein Liebhard LLP Reports

• 

Our Firm represents a number of Biomet hip replacement clients in this proceeding, and we continue to receive inquiries from others who were allegedly injured by the M2a Magnum hip.

New York, New York (PRWEB) May 25, 2014

Biomet hip lawsuits (http://www.consumerinjurylawyers.com/biomet-magnum-hip-replacement) involving the M2a Magnum Hip Replacement System continue to mount in a federal multidistrict litigation now underway in the U.S. District Court, Northern District of Indiana, Bernstein Liebhard LLP reports. According to an updated Docket Report issued by the U.S. Judicial Panel on Multidistrict Litigation on May 15, 2014, at least 2,210 Biomet hip replacement claims have been filed in the proceeding. This represents a significant increase since the Panel issued its April Docket Report, which noted just over 1,600 filings. (In re: Biomet M2a Magnum Hip Implant Products Liability Litigation – MDL No. 2391)

“Our Firm represents a number of Biomet hip replacement clients in this proceeding, and we continue to receive inquiries from others who were allegedly injured by the M2a Magnum hip,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to offer free and confidential legal consultations to individuals who may have been injured by metal-on-metal hip implants, including the Biomet M2a Magnum Hip Replacement System.

Biomet Hip Replacement Settlement
According to court documents, all of the Biomet hip lawsuits pending in the Northern District of Indiana were filed on behalf of individuals who allegedly suffered metallosis, pseudotumor formation, chronic pain, and other complications due to the metal-on-metal design of the M2A hip system. On February 3, 2014, the Court granted approval to a proposed Biomet hip settlement agreement, which if finalized would resolve hundreds of claims involving the device. Under the terms of the settlement, plaintiffs who received one of the affected Biomet hip replacements as part of an initial surgery that was revised more than 180 days after it was implanted would eligible for a base award of $200,000. In order to take effect, court papers indicate that the Biomet hip settlement must be accepted by 90% of eligible plaintiffs.

In January 2013, the U.S. Food & Drug Administration (FDA) warned that metal-on-metal hip implants may be more likely to fail prematurely compared to devices made from other materials. The agency has advised patients fitted with all-metal hip implants to undergo metal ion blood testing if they experience pain, swelling, or other symptoms that could be an indication that their hip is failing.

Recipients of the Biomet M2a Magnum hip may be eligible for compensation if they suffered metallosis, pseudotumor formation, chronic pain, premature device failure or other complications allegedly associated with its all-metal design. Find out more about the litigation involving Biomet hip replacements and other metal-on-metal hip implants by visiting Bernstein Liebhard LLP’s website. To arrange for a free case review, call 800-511-5092 to speak with a member of our legal staff.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.consumerinjurylawyers.com
https://plus.google.com/115936073311125306742?rel=author

PDF Print